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Abstract
Purpose: The clinical diagnosis and management of
invasive lobular carcinoma (ILC) of the breast presents
difﬁculties. Magnetic resonance imaging (MRI) has
been proposed as the imaging modality of choice for
the evaluation of ILC. Small studies addressing dif-
ferent aspects of MRI in ILC have been presented but
no large series to date. To address the usefulness of
MRI in the work-up of ILC, we performed a review of
the currently published literature.
Materials and methods: We performed a literature
search using the query ‘‘lobular AND (MRI OR MR
OR MRT OR magnetic)’’ in the Cochrane library,
PubMed and scholar.google.com, to retrieve all articles
that dealt with the use of MRI in patients with ILC. We
addressed sensitivity, morphologic appearance,
correlation with pathology, detection of additional le-
sions, and impact of MRI on surgery as different
endpoints. Whenever possible we performed meta-
analysis of the pooled data.
Results: Sensitivity is 93.3% and equal to overall sen-
sitivity of MRI for malignancy in the breast. Morpho-
logic appearance is highly heterogeneous and probably
heavily inﬂuenced by interreader variability. Correla-
tion with pathology ranges from 0.81 to 0.97; overes-
timation of lesion size occurs but is rare. In 32% of
patients, additional ipsilateral lesions are detected and
in 7% contralateral lesions are only detected by MRI.
Consequently, MRI induces change in surgical
management in 28.3% of cases.
Conclusion: This analysis indicates MRI to be valuable
in the work-up of ILC. It provides additional knowl-
edge that cannot be obtained by conventional imaging
modalities which can be helpful in patient treatment.
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Introduction
Invasive lobular carcinoma (ILC) is the second most
common histologic type of breast carcinoma after
invasive ductal carcinoma (IDC). In most series ILC
constitutes between 5 and 15% of all breast cancers,
whereas IDC constitutes between 70 and 90% of all
breast cancers [1–5]. Probably due to the use of com-
plete hormone replacement therapy the lobular breast
cancer component has continuously increased over the
past decade from 9.5% in 1987 to 15.6% in 1999 [3].
Patients are, according to most series, a little older
than patients presenting with IDC, especially the
fraction of patients presenting with ILC younger than
40 is smaller [1, 5, 6]. Furthermore, the mean tumor
size of ILC is slightly larger than in patients with IDC
and patient presentation with a tumor larger than 5 cm
occurs more often in cases of ILC [1, 5, 7].
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constituted from small, relatively uniform cells, very
similar to normal endothelial cells. Characteristically,
these cells are only loosely cohesive and inﬁltrate the
stromainsinglecellﬁlestrandsalongductuli.Thisgrowth
pattern, present in 30–77% of cases [8], is also known as
‘‘Indian ﬁling.’’ It is probably caused by a typical loss of
the adhesion molecule E-cadherin. Often there is very
little desmoplastic stromal reaction [8, 9]. The biological
characteristicsofILCareusuallylessalarmingthanthose
of IDC: more tumors contain estrogen receptors and
progesterone receptors, while expression of Her2/Neu
and p53 are more often normal and axillary lymph nodes
are not more often positive, even though ILC are overall
larger in size than IDC [1, 7].
Probably due to the diffuse inﬁltrative growth
pattern, ILC is frequently missed on mammography
[5]. Detection is also compromised because ILC
often has a density less than or equal to normal
ﬁbroglandular breast tissue on mammography [5, 10].
For correct treatment of ILC, adequate staging is
important. Both mammography and ultrasound tend
to underestimate lesion size and are therefore not
optimal for staging purposes [5, 11]. This may in part
be the reason that higher failure rates of breast-
conserving therapy (BCT) in ILC than in IDC are
reported [2, 11, 12]. Various authors therefore pro-
pose magnetic resonance imaging (MRI) as the
modality of choice for the evaluation of ILC. Several
small studies addressing the different aspects of the
use of MRI in ILC have been presented, but no large
series to date. Therefore many questions regarding the
use of MRI in ILC remain unanswered.
1. The sensitivity of MRI for breast lesions is
approximately 95–98%, however, whether this
holds true for ILC as well is not clear [13].
2. The morphologic aspects of ILC are not yet
well deﬁned, nor is the dynamic behavior of con-
trast agents in these tumors clearly documented.
3. Moreover, whether the MRI ﬁndings are similar to
pathologic ﬁndings and can thus be used for
accurate staging still needs to be established.
4. Finally, the impact of MRI on surgical treatment of
ILC should be evaluated.
To answer these questions we performed a
thorough review of the existing literature regarding
the use of MRI in case of ILC and performed
meta-analysis whenever possible. We subsequently
reviewed the literature on other imaging modali-
ties for this indication in order to evaluate the use
of MRI from a clinical perspective.
Materials and methods
Search strategy
We performed a literature search for articles that
speciﬁcally dealt with the use of MRI in patients with
histologic proof of ILC published before 1 April 2006.
The Cochrane Library, MEDLINE and the in-progress
citations as provided by PubMed were searched using
the query: ‘‘lobular AND (MR OR MRI OR MRT OR
magnetic).’’ These databases were further searched
using the ‘‘Related Articles’’ function in PubMed. The
same query was used to browse the web using
scholar.google.com.
Furthermore, the references of all retrieved articles
were manually searched for relevant cross-references.
Articles in all languages were accepted. All retrieved
articles were then compared and from overlapping
series of patients only the most recent publication was
accepted.
Many different search terms were used for literature
review of other imaging modalities. However, only
PubMed was used as search engine.
Endpoints
The study was thus undertaken to answer the following
four questions.
1. What is the sensitivity of MRI for ILC?
2. What are the visual characteristics of ILC on MRI?
3. Are the ﬁndings on MRI equal to the ﬁndings at
pathology?
4. What is the impact of MRI on surgical manage-
ment of ILC?
Whenever studies allowed direct comparison
between MRI and other imaging modalities, these
modalities were also analyzed. Sensitivity was deﬁned
as the number of lesions visible on MRI divided by the
total number of ILC detected at pathology. We
regarded morphology, dynamic curve analysis of con-
trast behavior, and quantitative dynamic analysis of
contrast behavior as three different aspects of tumor
appearance and these were thus analyzed separately.
A principal distinction between mass-like and non-
mass-like lesions was made in the analysis of
morphology. Based on the BI-RADS lexicon [14], we
deﬁned architectural distortion, regional, segmental,
ductal, multifocal, or diffuse enhancement, and multi-
ple enhancing foci as descriptors of non-mass lesions.
Nodular or focal enhancement, well-deﬁned, round,
irregular or spiculated masses, and dominant masses
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123with small enhancing foci were deﬁned as descriptors
of mass-like lesions. Correlation between the ﬁndings
on MRI and pathology was evaluated for relative
tumor size (unifocal versus multifocal disease and
single quadrant versus multicentric disease) and abso-
lute tumor size. The impact on surgical management
was derived from all changes implemented, based
solely on MRI ﬁndings. The numbers of correct and
incorrect changes were tabulated.
Eligibility criteria
All studies that presented a series of at least ten
patients with histologic proof of pure ILC, with or
without concurrent DCIS and/or LCIS, were consid-
ered eligible. A quality analysis of the study had to be
possible, otherwise no abstracts were accepted.
Patients with mixed carcinomas of ILC and IDC were
excluded. Studies that presented data on both ILC
and mixed carcinomas had to allow extraction of the
relevant data for ILC only. Every study considered
eligible according to these eligibility criteria was then
evaluated for all the study endpoints. Speciﬁc eligibility
criteria for the various considered endpoints are
described below.
Detection: Studies had to be based on a pathology
database and all subsequent patients with ILC
who underwent a MRI had to be included. The
total number of ILC conﬁrmed at pathology had
to be clearly stated as well as the number of
lesions found with MRI.
Morphology: Studies describing the appearance
of ILC visible on MRI were eligible. Separation
between mass and non-mass-like lesions had to be
possible.
Dynamic curve analysis of contrast behavior:
Studies that described the enhancement versus
time curve were eligible. However, as time to
peak and shape of the ﬁnal phase of the
enhancement curve were our main endpoints,
these had to be described.
Quantitative analysis of contrast behavior: Studies
performing quantitative analysis of the contrast-
enhancement parameters were eligible.
Relative correlation with pathology: Studies pre-
senting data on the unifocal versus multifocal
correlation or single quadrant involvement versus
multicentric involvement were eligible.
Absolute correlation with pathology: Studies
comparing sizes measured on MRI with
those measured at pathology and presenting a
correlation coefﬁcient or sufﬁcient raw data to
calculate such a value were eligible.
Detection of additional lesions: Any study
describing additional lesions apart from the index
lesion detected by MRI only with subsequent
acquisition of histologic proof of malignancy was
considered eligible. Lesions in the ipsilateral
breast and the contralateral breast were evaluated
separately.
Impact on surgical treatment: Studies mentioning
all changes in surgical strategy based on MRI
ﬁndings were eligible.
Statistics
The quality of all included studies was assessed using
the QUADAS tool [15]. The latter is a list of 14 items
created for quality assessment of studies to diagnostic
accuracy. Although not all the included studies spe-
ciﬁcally evaluate diagnostic accuracy, this tool was
judged to be the most appropriate available. Data of all
the studies were collected according to the inclusion
and exclusion criteria. When at least ﬁve studies pre-
sented the same type of data or at least 100 patients
were included in a smaller series of studies with similar
data, we considered meta-analysis and heterogeneity
analysis was performed. Dichotomous data with a
binomial distribution (e.g., sensitivity) were trans-
formed to the log odds scale because this scale has a
normal distribution and is a good approximation to the
exact binomial distribution. A disadvantage of this
transformation, however, is that the conﬁdence inter-
vals are a little wider and values in the middle of the
distribution (e.g., sensitivity closer to 50%) are more
heavily weighted in meta-analysis than values close to
the upper or lower level. Pearson’s correlation coefﬁ-
cient was transformed to Fisher’s Z for the same
reason [16].
We calculated Cochran’s Q coefﬁcient and the
I
2-statistic to assess heterogeneity. Cochran’s Q is a
form of the v
2-test and provides information about the
applicability of pooling the data. The I
2-statistic pro-
vides a quantitative measure of the amount of heter-
ogeneity and has an upper limit of 100%. Values of the
I
2-statistic of 25, 50, and 75% can be interpreted as low,
moderate, and high heterogeneity, respectively [17].
Meta-analysis of the data using a random effects model
was performed when the Q-coefﬁcient showed no
signiﬁcant heterogeneity (p > 0.05).
In cases where meta-analysis was feasible, the
estimate and the 95% CL are expressed. When
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geneity, only the range of values found in the different
studies is mentioned. All calculations were performed
using R version 2.3.1 (The R Project for Statistical
Computing, www.r-project.org) and the meta package
(G. Schwarzer, cran.r-project.org).
Results
Studies
We identiﬁed 21 separate studies that dealt with MRI
and ILC [18–38]. We further identiﬁed four studies that
did not deal speciﬁcally with ILC and MRI. However,
they did present their data in such a fashion that rel-
evant information for ILC only could be extracted for
at least ten patients [39–42]. Four studies were case-
reports and were dropped from the cohort [20, 21, 29,
37]. The study by Bazzocchi et al. [18] was excluded
because only eight patients underwent MRI. Leung
et al. [27] and Newstead et al. [42] only published
their ﬁndings in abstract form and were conse-
quently excluded. Table 1 gives an overview of the
included studies and their characteristics, including the
QUADAS score.
The applied scan protocols in the included studies
are diverse. In general, most studies presented herein
used a 1.5-T MRI scanner, although some authors had
at least some of their included patients scanned using
1.0 T machines [33, 34, 40]. Most protocols were based
on T1 weighted images made with either a normal
FLASH 3D sequence or a FLASH 3D sequence with
fat-suppression [19, 20, 23, 24, 26, 31, 33–36, 38, 40, 41]
or a RODEO sequence with water selective excitation
[25, 30, 32]. A number of authors also used T2
weighted sequences [22, 23, 31, 38, 40, 41]. Other dif-
ferences in scan protocols involve the voxel sizes and
temporal resolution. Some authors emphasize high
spatial resolution [32, 39] while others prefer high
temporal resolution [26] and yet again others per-
formed both types of sequences in succession [30, 38].
Furthermore, single breast coils [26, 30, 32, 36, 41, 43]
and double breast coils (all others) were used and
sometimes compression was applied to the imaged
breast [31, 36, 39]. In most reported studies the scan-
ning protocols evolved over time and are thus not
identical for all imaged patients.
Lesion detection
Eight studies provided sufﬁcient data to calculate
sensitivity of MRI for ILC [19, 23, 24, 26, 28, 33, 34, 40].
Sensitivity ranged from 83 to 100%. Cochran’s Q was
6.48 (p = 0.49), I
2 was 0%, indicating homogeneous
studies and hence data pooling could be performed.
Mean sensitivity was 93.3% (95% CI 88–96%). Only
the studies by Francis et al. [24] and Berg et al. [40]
provided prospective data and are therefore able to
show sensitivity in clinical practice. They showed a
sensitivity of 95 and 97%, respectively, and were sta-
tistically not different from the retrospective studies
(two-sided T-test, p = 0.78). Seven of these studies also
provided data on mammography [Q 31.79 (p < 0.001),
I
2 = 81%], six on ultrasound [Q 10.92 (p = 0.05),
I
2 = 54%], and ﬁve on clinical examination [Q 29.63
(p < 0.001), I
2 = 87%]. Sensitivity of ultrasound could
also be computed through meta-analysis and was 83%
(95% CI 71–91%), although moderate heterogeneity
was present. The provided data for mammography and
clinical examination were too heterogeneous for meta-
analysis and ranged from 34 to 91 and 28 to 94%,
respectively. Figure 1 shows the results of each inde-
pendent study and the overall results.
Morphology
Seven studies described lesion morphology on static
MRI images [23, 30, 32, 33, 36, 38, 41]. However, Kim
et al. [41] studied morphologic appearances of masses
onlyandthereforedidnotincludenon-mass-likelesions.
Information provided by their study is therefore only
used to evaluate the appearance of masses and not for
the principal distinction between mass and non-mass
lesions. The terminology used in the literature to
describe the lesions is highly variable. Only Yeh et al.
[38] consistently used the terminology of the BI-RADS
lexicon [14]. The six eligible studies that presented data
on morphologic appearance described a total of 133 tu-
mors. However, results are highly variable. The inci-
dence of a mass-like lesion ranged from 31 to 95%
[Q 16.44 (p < 0.01), I
2 = 70%]. Table 2 shows the
appearance of ILC on MRI for all individual studies.
Fabre Demard et al. [23] did not specify the lesions
beyond the description ‘‘mass-like.’’ Other authors
used many different terms to further describe lesions.
In the study presented by Rodenko et al. [32], ﬁve pre-
deﬁned shapes were used, but they described all 19
mass-like lesions as spicular enhancing masses. In the
other studies most lesions are described as spiculated
masses as well. Schelfout et al. [33] recognized a
dominant mass with multiple enhancing foci in eight
cases and Yeh et al. [38] described even a round focal
mass. In the 12 mass-like cases described by Kim et al.
[41], 10 had an irregular shape and 8 were spiculated.
Therefore, among the 76 masses, a total of 65 tumors
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123were described as an irregular or spiculated mass. This
appears to be the most common type of mass-like
presentation in ILC.
Kinetics
Only two studies reported on the dynamic curve
appearance of ILC [34, 35]. The most apparent simi-
larity between ﬁndings was that maximum enhance-
ment is often delayed and wash-out is present in only a
minority of lesions. Sittek et al. [34] reported that
maximum enhancement was not reached before 2 min
after contrast administration. Trecate et al. [35] noted
that a classic pattern of rapid signal increase was only
present in 4 of 12 pure ILC, whereas a delayed pattern
was observed in the other 8 cases.
Two other studies reported on quantitative contrast
behavior analysis in ILC [30, 38]. Qayyum et al. [30]
reported on a parameter called K21, analogue to the
K
trans parameter as described by Tofts et al. [44]. Yeh
et al. [38] evaluated the extraction ﬂow product (EFP),
which is a similar analogue but respects the possibility
that contrast leakage from the vessels is limited by ﬂow
instead of being limited by the permeability surface
area product. Both studies did not, however, include
sufﬁcient patients to produce meaningful results, other
than a high variability in the values of these parameters
and the presence in some tumors of enhancement very
Table 1 Characteristics of the included studies
Authors Pub.
Year
a
Study
type
b
N
c Age
mean
d
Age
min.
e
Age
max.
f
Field
g Scan
seq.
h
Uni/
bilat
i
Compression
j Mean
size
k
QUADAS
score
l
Rodenko et al.
[32]
1996 1 20 60 38 84 2 1 1 0 X 11
Sittek et al. [34] 1998 1 23 X X X 1 2 2 0 X 11
Weinstein et al.
[36]
2001 1 17 53 32 69 2 2 1 1 1,7 12
Kim et al. [41] 2001 1 12 54
m 24
m 88
m 2 2 1 0 2,1
m 12
Trecate et al. [35] 2001 1 28 X 32 81 2 2 2 0 X 9
Francis et al. [24] 2001 2 22 X X X 2 2 2 0 3,7 12
Qayyum et al. [30] 2002 1 13 55 46 84 2 1 1 0 X 11
Munot et al. [28] 2002 1 20 61 39 78 2 3 2 0 X 11
Yeh et al. [38] 2003 1 19 59 42 79 2 2 2 0 4,1 11
Kneeshaw et al.
[26]
2003 1 21 57 43 72 2 2 1 0 X 11
Quan et al. [31] 2003 1 62 53 X X 2 2 3 1 X 10
Bedrosian et al.
[39]
2003 1 24 53
m XX 2 0 01 X 1 0
Schelfout et al.
[33]
2004 1 26 57 41 74 3 2 2 0 X 11
Diekmann et al.
[22]
2004 1 17 X X X 0 0 0 0 X 10
Boetes et al. [19] 2004 1 34 55 35 78 2 2 2 0 4,9 10
Berg et al. [40] 2004 2 29 X X X 3 2 2 0 X 13
Kepple et al. [25] 2005 1 29 62 51 67 2 1 3 0 X 9
Fabre Demard
et al. [23]
2005 1 34 X X X 2 2 2 0 X 11
a Year of publication of the original article
b 1 indicates retrospective cohort study, 2 indicates prospective cohort study
c Number of patients included
d Mean age of all included patients, X denotes not mentioned
e Age of respective youngest patient included in the study
f Age of respective eldest patient included in the study
g Strength of magnetic ﬁeld—0 denotes unknown, 1 denotes 1 T, 2 denotes 1.5 T, 3 denotes both 1 T and 1.5 T
h Type of scan sequence used—0 denotes unknown, 1 denotes RODEO, 2 denotes FLASH 3D, 3 denotes other
i Unilateral or bilateral imaging of the breast—0 denotes unknown, 1 denotes unilateral, 2 denotes bilateral, 3 denotes both unilateral
and bilateral depending on the patient
j Compression applied to the breast—0 denotes no, 1 denotes yes
k Mean size of the lesions in centimeters, X denotes not mentioned
l Number of items valid on QUADAS scorings list
m Valid for whole study population only, not for subpopulation of patients with ILC
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123much like enhancement in normal breast tissue. It was
noted that K21 values appeared to be an order of
magnitude less in ILC than in IDC lesions.
Correlation
Several authors evaluated correlation of the MRI
ﬁndings with pathology [19, 24–26, 28, 32, 33, 40].
Three studies compared unifocality and multifocality
between MRI and pathology [26, 32, 33] (Table 3).
Overall 5 of 67 cases (7%) were regarded as multifocal,
whereas they appeared unifocal at pathology and, vice
versa, 2 cases (3%) in one study appeared unifocal at
MRI, but were multifocal according to pathology.
Overestimation of multifocality based on mam-
mography in 63 patients from these studies occurred in
2 patients (3%), whereas underestimation occurred 25
times (40%) and the lesion was not visible on mam-
mography in another 4 patients (6%).
Two of these studies further analyzed single quad-
rant versus multicentric involvement of the affected
breast [32, 33] (Table 4). In the study by Rodenko
Fig. 1 Forestplot of the sensitivity of the respective modalities
for ILC (MMG mammography, US ultrasound, CE clinical
examination), the horizontal lines represent 95% conﬁdence
intervals. Modalities presented on the right of the authors name
have not been tested in the appropriate study. The diamonds at
the bottom represent the pooled estimates and their 95%
conﬁdence intervals for MRI and US, respectively. Because
mammography and clinical examination were too heterogeneous
for meta-analysis no pooled estimate is presented for these
modalities
Table 2 Morphologic
appearance of ILC on MRI
Numbers between parenthesis
represent percentages
Authors Number of tumors Non-mass-like Mass-like
Rodenko et al. [32] 20 1 (5) 19 (95)
Weinstein et al. [36] 18 8 (44) 10 (56)
Qayyum et al. [30] 13 9 (69) 4 (31)
Yeh et al. [38] 20 11 (55) 9 (45)
Schelfout et al. [33] 27 6 (22) 21 (78)
Fabre Demard et al. [23] 35 11 (31) 24 (69)
Table 3 Relative correlation of unifocality versus multifocality for MRI versus pathology
Authors Number of patients UF MRI UF PATH MF MRI MF PATH Overestimated
a Underestimated
b
Rodenko et al. [32] 20 9 11 11 9 2 1
Kneeshaw et al. [26] 21 9 10 12 11 1 0
Schelfout et al. [33]2 6 1 4 1 7 1 2 1 0 2 1
Total 67 5 2
UF unifocal, MF multifocal, PATH pathology
a Disease was classiﬁed as multifocal on MRI, but was unifocal on pathology
b Disease was classiﬁed as unifocal on MRI, but was multifocal on pathology
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123et al. [32], two cases of single quadrant disease were
erroneously classiﬁed as multicentric on MRI.
Mammography in 42 of these patients resulted in
overestimation of disease extent in 1 patient and
underestimation in 15. Again, no lesion was visible in
four patients.
Berg et al. [40] further showed a series of 12 patients
that underwent MRI. Correct size estimation was
performed in seven patients. In one patient an addi-
tional focus was missed and in four patients overesti-
mation occurred due to foci of LCIS.
Absolute correlation of MRI and pathologic size
measurement was performed by six authors [19, 24–26,
28, 32]. Rodenko et al. [32] found a Kappa coefﬁ-
cient of 0.77, which represents substantial agreement.
The other authors presented Pearson’s correlation
coefﬁcients ranging from 0.81 to 0.97 [Q 10.90
(p = 0.03), I
2 = 63%]. Correlation coefﬁcients for
other modalities were substantially more variable.
Presented correlation coefﬁcients in Table 5 are
optimized by excluding cases where no abnormalities
were seen from the calculations.
Boetes et al. [19] applied a correctness measure of
1.0 cm to their data and found that MRI underesti-
mated disease extent in 5 of 36 tumors and overesti-
mated extent in 4 cases by more than 1.0 cm. The data
provided by Francis et al. [24] allow a similar calcula-
tion. Underestimation occurred in 6 of 22 cases and
overestimation occurred in 1.
Additional lesions
Five studies focused on the detection of concurrent
additional lesions in the affected breast apart from the
index lesion only visible by MRI [22, 23, 31, 33, 36]. In
44 of 146 patients, additional malignant lesions were
found [Q 7.20 (p = 0.13), I
2 = 44%]. Additional
malignant ﬁndings only visible on MRI were present in
32% of cases (95% CI 22–44%). The results of the
individual studies are presented in Table 6.
Eight studies, presented in Table 7, reported on
ﬁndingsinthecontralateralbreast[19,22–25,28,31,40].
In 12 of 206 patients, unexpected contralateral cancer
was discovered exclusively by MRI [Q 2.28 (p = 0.94),
I
2 = 0%]. Cases where contralateral cancer was also
visible on mammography and/or ultrasound are
excluded. Contralateral carcinoma only visible by MRI
was present in 7% of patients (95% CI 4–12%).
Effect on surgical treatment
Six studies explicitly stated the effect of MRI on the
surgical treatment of their patients [23, 26, 28, 31,
32, 39]. In 160 patients with ILC, a total of 44
changes in surgical management occurred [Q 7.90
(p = 0.16), I
2 = 37%]. Overall, MRI changed the
surgical management in 28.3% of cases (95% CI
20–39%). In 24 cases BCT was changed to mastec-
tomy. In nine cases a wider local excision was per-
formed. In the remaining 11 cases the type of change
was not further described. Forty-one of 44 changes in
surgical management were retrospectively judged
necessary based on pathologic ﬁndings [Q 1.24
(p = 0.94), I
2 = 0%]. Therefore, 88% of all changes
were correct (95% CI 75–95%). In three cases the
change in management was retrospectively judged
unnecessary based on pathology. The data of the
individual studies are presented in Table 8.
Rodenko et al. [32] and Kneeshaw et al. [26] both
reported one further unnecessary mastectomy based
on MRI outcomes. However, these mastectomies
would also have been performed based on the
mammography ﬁndings and are therefore not only
due to the MRI. Berg et al. [40] also reported that
ﬁndings on MRI in 12 patients with ILC would have
resulted in two unnecessary mastectomies. However,
mastectomies were also indicated according to the
ultrasound report. Nonetheless they based their
treatment on the mammograms only and therefore
these mastectomies were not performed.
Table 4 Relative correlation of single quadrant versus multicentric involvement for MRI versus pathology
Authors Number
of patients
SQ MRI SQ PATH MC MRI MC PATH Overestimated
a Underestimated
b
Rodenko et al. [32] 20 9 11 11 9 2 0
Schelfout et al. [33]2 6 2 1 2 1 5 5 0 0
Total 46 2 0
SQ single quadrant, MC multicentric, PATH pathology
a Multicentric involvement was seen on MRI, but involvement of only one quadrant was shown on pathology
b Involvement of only one quadrant was seen on MRI, but on pathology multicentric involvement was shown
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Studies and quality analysis
We included 18 studies, but the highest number of
studies that could be used to answer a speciﬁc endpoint
was 8 (sensitivity and contralateral ﬁndings). Strong
evidence is therefore lacking and this review is thus a
clear call for more substantial research in this area. The
overall study quality of all studies is, according to the
QUADASscore,reasonablyhigh(lowestscore = 9/14).
However, this tool does not include the study size in
the analysis, which was generally low. The tool places a
strong emphasis on the relation of the test to the
reference standard (typical for observational studies).
In all studies, the reference standard was pathology
and therefore always acceptable as gold standard.
However, the test results (in this case the MRI
reports), were never shielded from the pathologist who
performed the pathologic evaluation. In studies that
were performed to evaluate the visual characteristics of
ILC on MRI a thorough description of the pathological
examination was, deservedly so, not included [23, 30,
32, 33, 36, 38, 41]. These studies thus scored a little
lower. There are some other drawbacks that must be
considered and that are not included in the QUADAS
score. Firstly, all but 2 of the included 18 studies were
retrospective in nature, and secondly, the applied MRI
protocols were largely heterogeneous (see Table 1).
However, the presented data were extracted from
studies that made use of the various standards in MRI
of the breast of the last decade and therefore give a
reasonable overview of the overall capability of MRI in
ILC imaging in this period.
Sensitivity
The sensitivity of physical examination and conven-
tional imaging for ILC of the breast is not optimal. The
sensitivity of physical examination for ILC ranges
between 65 and 98% [10, 45–47], with usually over
50% of patients presenting with palpable abnormalities.
The sensitivity of mammography for ILC (BI-
RADS 3 or higher) ranges between 81 and 92% in
literature [10, 45–51]. In a recent study that evaluated
intra- and interobserver variability, sensitivity even
ranged from 88 to 98% [52], which could be regarded
as sufﬁcient. However, ILC often do not appear as a
malignant lesion on mammography; approximately
30% is classiﬁed as equivocal and sensitivity is then
approximately 57–59% [51].
Table 5 Correlation of tumor size measured by various modalities compared to pathology
Authors MRI MMG US CE
N PCC K N PCC KN PCC KN PCC K
Rodenko et al. [32] 20 0.773 15 –0.081
Munot et al. [28] 20 0.97 10 0.66 14 0.67
Kneeshaw et al. [26] 21 0.86 21 0.93
a 21 0.93
a 21 0.47
Francis et al. [24] 22 0.87 16 0.79 20 0.56 19 0.89
Boetes et al. [19] 36 0.81 36 0.34 36 0.24
Kepple et al. [25] 33 0.88 9 0.71
MMG mammography, US ultrasound, CE clinical examination, N number of lesions visible on the appropriate modality,
PCC Pearson’s correlation coefﬁcient, K Kappa value
a Kneeshaw et al. did not provide a correlation coefﬁcient for either MMG or US, but only one for the combined modalities
Table 6 Additional malignant ﬁndings in the ipsilateral breast
by MRI
Authors Number
of patients
Number of
additional ﬁndings
Weinstein et al. [36]1 8 7
Quan et al. [31]5 1 1 1
Schelfout et al. [33]2 6 9
Diekmann et al. [22]1 7 9
Fabre Demard et al. [23]3 4 8
Total 146 44
Meta-analysis (%) 100 32
Table 7 Additional ﬁndings in the contralateral breast by MRI
Authors Number of
patients
Number of
contralateral ﬁndings
Francis et al. [24]2 20
Munot et al. [28]2 0 2
Quan et al. [31]5 3 5
Diekmann et al. [22]1 7 1
Boetes et al. [19]3 42
Berg et al. [40]1 5 0
Kepple et al. [25]1 40
Fabre Demard et al. [23]3 4 2
Total 206 12
Meta-analysis (%) 100 7
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123The overall sensitivity of mammography in the
current analysis appears lower than ﬁndings in the lit-
erature on mammography in ILC. However, equivocal
ﬁndings may have been classiﬁed as undetected lesions
in some studies resulting in the overall lower results.
Nevertheless, the sensitivities of only 34% found by
Berg et al. [40], and 50% found by Munot et al. [28] are
on the lower end of the spectrum. Munot et al. [28] did
not state which views constituted their mammograms,
while Berg et al. [40] made craniocaudal, mediolateral
and spot-compression views on a standard mammog-
raphy machine, which we regard as common practice.
A possible explanation for the poor results in the study
by Berg et al. [40] may be that they deﬁned an ILC as a
focus of tumor, thereby allowing more tumors to be
present in one breast, whereas other authors deﬁned
this as multifocal or multicentric tumors and thus as
detected when at least one lesion was visible on
mammography.
In literature, the reported sensitivity of ultrasound
for ILC ranges between 68 and 98% [47, 53–58]. As
this range is comparable to the range found in the
present evaluation, we are of the opinion that an
overall sensitivity of 83% is accurate. However,
application of newer high-frequency ultrasound trans-
ducers may improve sensitivity. Initial series using
7.5 MHz transducers show sensitivities of 68% [47] and
78% [56], whereas series that used 10–13 MHz trans-
ducers report sensitivities up to 98% [57, 59].
Contrast-enhanced MRI is nowadays widely
accepted as the most sensitive modality for detection of
malignancy of the breast. Early reports on overall
sensitivity of MRI for breast lesions range from 93 to
100% [13, 60–63]. Thus, the sensitivity of MRI found
for ILC in the studies presented herein and the overall
sensitivity of 93.3% calculated from these studies are
not different from those known for malignancy in the
breast in general. The relatively low heterogeneity of
all studies describing lesion detection as well as
detection of additional lesions in the ipsi- and contra-
lateral breast show that the applied MRI technique
only has a minor impact on the ability of MRI to detect
lesions.
The overall sensitivity could even be increased to
96% (95% CI 92–98%) if an early study is excluded
from the analysis [34]. This study reported a sensitivity
for ILC of only 83%, a discrepancy that may well be
explained by the fact that the slice thickness in this
study was 4.2 mm, thicker than in any of the other
presented studies, which could have had a negative
impact on sensitivity. Moreover, 15 of 23 patients in
their series were scanned with a FLASH 3D sequence
with TR 8.4/TE 3.0, resulting in image acquisition with
a phase-shift of water and fat, which might have further
decreased their sensitivity, although this was not
apparent from their data.
It must be taken into account that the acquired
sensitivity in all studies was achieved in cases where
prior knowledge of the existence of ILC was present.
Mostly because of the retrospective nature of the
presented studies, but also because the two prospective
studies both included their patients on the basis of
histological proof of invasive (lobular) carcinoma by
core biopsy. It is therefore not possible to formulate
conclusions on the sensitivity of MRI for ILC prior to
biopsy. In a large multicenter trial by Bluemke et al.
[64] overall sensitivity for invasive cancer prior to
biopsy was 91%, thus it might be expected that sensi-
tivity for ILC prior to biopsy is also slightly lower.
However, in most cases the indication for MRI is
Table 8 Changes in surgical management based solely on MRI ﬁndings
Authors Number
of
patients
Number
of
changes
Correct
changes
Incorrect
changes
Correct
wider
excision
Incorrect
wider
excision
Correct
mastectomy
Incorrect
mastectomy
Rodenko et al. [32]2 08 7 1 7 1
Munot et al. [28]2 0 3 3 3
Kneeshaw et al. [26]2 1 55 1 4
Quan et al. [31]5 1 1 1 1 1 5 6
Bedrosian et al. [39] 2 41 192 N A N A N A N A
Fabre Demard et al. [23]2 4 6 6 3 3
Total 160 44 41 3 9 23 1
Number of changes (%) 100 28.3
Correct changes (%) 100 88
Number of changes and correct changes show the result of meta-analyses
NA not available
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123assessment of disease extent because of inconclusive
ﬁndings at mammography or ultrasound. In conclusion,
the sensitivity of MRI for ILC is higher than that
achieved by any other modality, in direct comparison
and validated by literature, and is equal to the overall
sensitivity of MRI for malignant lesions of the breast.
Only modern ultrasound examinations seem to have
the ability to approach the performance of MRI in the
detection of ILC [57].
Morphology
The morphologic appearance of ILC on MRI ranged
from 69% non-mass-like lesions to 95% mass-like
lesions, thereby raising questions concerning the
amount of heterogeneity in the description of
morphology of lesions by radiologists. In fact, the
general agreement on the description of lesion type
according to the BI-RADS lexicon is only moderate
[14, 65]. In the current analysis, this is even further
complicated because most authors did not speciﬁcally
use the BI-RADS lexicon. Additionally, differences in
scan techniques may have further affected the
appearance of the lesion. However, in keeping with
the above, the classiﬁcation of lesion type is also
highly variable on mammography, where the incidence
of mass lesions ranges from 32 to 78% [10, 45, 46, 48,
50, 51, 55].
The vast majority of the mass-like lesions described
on MRI are irregular or spicular lesions. The eight pa-
tients with a dominant mass surrounded by multiple
enhancing foci, as described by Schelfout et al. [33], may
present noncontiguous foci of disease without visible
spiculae due to the absence of desmoplastic reaction,
which is a well-known histopathological presentation
[8]. In all series only one round mass was described [38],
suggesting this to be a very rare presentation for ILC.
This is consistent with ﬁndings in mammography by Le
Galetal.[10],whodescribedaroundmassinonly2%of
all patients where a mass was present (4/174) while the
remainder was either classiﬁed as a spicular mass (54%)
or poorly deﬁned mass (44%).
Mammographic ﬁndings would therefore appear to
correlate well with MRI ﬁndings. However, only one
study allows direct comparison [33]: of all lesions visi-
ble in this study on both mammography and MRI, 78%
(18/23) were classiﬁed as mass-like by MRI, while only
48% (11/23) were classiﬁed as mass-like by mammog-
raphy. Six masses on MRI were visible as architectural
distortion on mammography and two as asymmetric
density. In one case a lesion described as spicular mass
on mammography was visible on MRI as multiple
enhancing foci with interconnecting enhancing strands.
Non-mass-like ILC in mammography are typically
described as architectural distortion or asymmetric
density. In some cases microcalciﬁcations are present,
although these are often related to concurrent sur-
rounding DCIS, sclerosing adenosis or ﬁbrotic changes
and might thus not be related to the presence of ILC
[45, 51, 55]. The descriptors currently used for non-
mass-like lesions on MRI are diverse and include var-
ious types of abnormal enhancement, such as regional,
ductal, segmental, and diffuse enhancement. Accord-
ing to Qayyum et al. [30] the morphologic description
of ILC on MRI has a good correlation to histopatho-
logic ﬁndings. The non-mass-like presentation might
speciﬁcally occur in cases where ILC grow in the classic
pattern with cells arranged in a linear fashion along the
ductuli.
It may thus be concluded that the appearance of
most ILC on MRI and mammography is similar: most
ILC are mass-lesions that have clear malignant prop-
erties. However, the more diffuse growing tumors are
characterized by areas of unexpected enhancement
and are more difﬁcult to recognize. In a number of
cases where no clear mass is visible on mammography,
a mass-like lesion may be found on MRI [33].
Kinetics
The relatively late contrast enhancement of ILC
apparent in all studies presented here and mirrored
by the relatively low values of K21 and EFP in the
studies by Qayyum et al. [30] and Yeh et al. [38]
must be taken into account when evaluating ILC.
Standard subtraction images, generated from the
pre-contrast and the ﬁrst or second post-contrast
acquisitions may be inconclusive as maximum
enhancement is not achieved at this point in time
and the lesion is thus not yet clearly visible. In fact,
false-negative MRI in cases of ILC is usually
contributed to inadequate enhancement of the tumor
[26, 35, 66]. The diffuse and often slow tumor
growth, not requiring extensive neovascularization,
may partly cause this difﬁcult visualization [1, 67, 68].
This is also clear from the relatively lower amount of
vascular endothelial growth factor found in tumors
with a lobular histology, which might also indicate a
different signaling pathway in the formation of neo-
vascular vessels in ILC, resulting in more mature and
thus less leaky capillaries [69], with consequently
diminished or absent contrast enhancement.
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In the herein presented studies overestimation of
lesion extent by mammography is rare, yet underesti-
mation is more rule than exception. This is also con-
ﬁrmed by studies that speciﬁcally deal with
mammography in cases of ILC. Yeatman et al. [5]
showed that mammography underestimated ILC by a
mean of 12 mm. Uchiyama et al. [51] reported 56% of
all visible ILC on mammography to be underestimated
and Veltman et al. [52] showed 35–37% of all ILC to
be mammographically understaged.
Ultrasound also tends to underestimate tumor size
in the studies presented here. This ﬁnding is underlined
by Tresserra et al. [70] and more recently by Water-
mann et al. [71], who documented a structural under-
estimation of 5.4 ± 12.2 mm in cases of ILC versus
1.4 ± 12.0 mm for cases of IDC. This might be partly
due to the observation that US tends to underestimate
larger tumors more than smaller tumors and low grade
tumors more than high grade [70], consistent with the
ﬁnding that ILC usually presents with slightly larger
and less aggressive tumors [1, 5, 67, 72]. The current
analysis shows that there is good correlation of tumor
size measured on MRI compared to pathology. The
various studies presented only moderately heteroge-
neous results.
In most cases MRI outperforms mammography
and ultrasound in the assessment of disease extent.
Most tumors are correctly classiﬁed as uni- or
multifocal and multicentric disease is only seldom
overestimated [19, 32].
Additional lesions and effect on surgical treatment
Especially important in this analysis is the detection of
additional lesions apart from the index lesion in
patients with ILC. The co-existence of other invasive
malignant lesions apart from the index lesion in the
ipsilateral breast in 32% of patients only visualized by
MRI is high. Moreover, the detection of contralateral
cancer in another 7% of patients by MRI only, seems
to make MRI indispensable. These ﬁndings are con-
ﬁrmed by the rate of change in treatment of the
ipsilateral breast based on MRI. The fact that change
in treatment was considered correct, as veriﬁed
by pathologic ﬁndings in the specimen, in 88% of cases
shows that ILC is often more extensive than appreci-
ated on conventional imaging.
However, various authors have shown that there is
no signiﬁcant difference in disease free survival (DFS)
or overall survival (OS) after BCT or mastectomy in
patients with breast cancer. Although some authors
report more local recurrence in patients with ILC after
BCT [2, 73], most authors showed that there is no
difference in DFS or OS after BCT in ILC versus IDC
[74, 75]. On the other hand, Yeatman et al. [5] reported
a higher rate of conversion from lumpectomy to mas-
tectomy in ILC compared to IDC (17.5% versus 6.9%).
More recently, Molland et al. [68] reported similar
ﬁndings (37.2% versus 22.4%). Hussien et al. [2] even
reported failure of BCT in patients with ILC in 63%
(34/54) of patients, resulting in conversion to mastec-
tomy in 76% of failures (26/34). However, a very
recent study by Morrow et al. [76] showed that BCT
did not fail more often in patients with ILC when
corrected for age and tumor size, although they still
observed a trend of more excisions in patients with ILC
[OR 1.58 (0.89–2.79), p = 0.12].
To date, there is no evidence suggesting increase in
survival for patients with ILC due to the performance
of MRI. What is then the added value of MRI? The
rate of recurrence 10 years after BCT followed by
radiotherapy is between 7 and 18% and is not signiﬁ-
cantly different from the rate of recurrence in case of
IDC [77, 78]. However, in view of the MRI ﬁndings
(additional malignant lesions in 32% of patients), we
can only conclude that in a large number of patients
with ILC, surgery is not curative but merely debulking.
As recurrence rates are fortunately much lower, we
must assume that curative treatment is to be expected
from adjuvant therapy. Unfortunately, because there is
no possibility to determine which additional ﬁndings
will respond to adjuvant therapy, the detection of
additional lesions on MRI currently still requires a
change of treatment when malignancy has been proven
by core biopsy. This may further reduce the rate
of recurrence in patients with ILC and may even
improve survival. However, this requires conﬁrmation
in future studies.
Conclusion
Magnetic resonance imaging has a high sensitivity for
ILC, not achieved by other imaging modalities. There-
foreMRIishelpfulincaseswhereconventionalimaging
is inconclusive. Morphology is often mass-like and a
typical ILC presents as an irregular or spiculated mass.
However, asymmetric enhancement that can be ductal,
segmental,regional,ordiffuseinnaturemaybetheonly
sign of tumor. MRI measures disease extent with a high
reliability. Although underestimation and overestima-
tionoflesionsizebyMRIstilloccurs,itismoreaccurate
than size determination by other modalities, indicating
often more extensive tumor burden than expected.
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results in more failure of BCT, more re-excisions and
more conversion to mastectomy in series where MRI is
not used. MRI has an effect on surgical management in
that when used to assess disease extent, surgical
management was changed in 28.3% of which 88% were
judged necessary based on pathology. Larger series of
patients are required to conﬁrm the ﬁndings of this
review; especially evaluation of tumor morphology and
dynamic proﬁle seems feasible.
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